Cushing's Syndrome — A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
Citation(s)
A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease